Avrobio Inc (AVRO)
16.80
-0.24
(-1.41%)
USD |
NASDAQ |
Jun 20, 16:00
1.39
-15.41
(-91.73%)
After-Hours: 20:00
Avrobio Research and Development Expense (TTM): 31.05M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 31.05M |
| December 31, 2023 | 47.70M |
| September 30, 2023 | 61.45M |
| June 30, 2023 | 62.54M |
| March 31, 2023 | 70.27M |
| December 31, 2022 | 72.19M |
| September 30, 2022 | 73.05M |
| June 30, 2022 | 80.17M |
| March 31, 2022 | 83.84M |
| December 31, 2021 | 83.11M |
| September 30, 2021 | 83.70M |
| June 30, 2021 | 89.17M |
| March 31, 2021 | 87.49M |
| Date | Value |
|---|---|
| December 31, 2020 | 87.24M |
| September 30, 2020 | 84.87M |
| June 30, 2020 | 69.40M |
| March 31, 2020 | 60.80M |
| December 31, 2019 | 54.97M |
| September 30, 2019 | 50.56M |
| June 30, 2019 | 46.75M |
| March 31, 2019 | 41.89M |
| December 31, 2018 | 35.10M |
| September 30, 2018 | 28.75M |
| June 30, 2018 | 24.93M |
| March 31, 2018 | 19.40M |
| December 31, 2017 | 15.19M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
31.05M
Minimum
Mar 2024
89.17M
Maximum
Jun 2021
69.02M
Average
71.23M
Median
Research and Development Expense (TTM) Benchmarks
| Agenus Inc | -- |
| BioCryst Pharmaceuticals Inc | 214.67M |
| AIM ImmunoTech Inc | 10.84M |
| Protalix BioTherapeutics Inc | 14.13M |
| Armata Pharmaceuticals Inc | 32.18M |